Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old (inclusive)
• People who have been diagnosed with a type of B-cell non-Hodgkin lymphoma (a blood cancer) that has been confirmed by laboratory testing to carry a marker called CD19
• People whose lymphoma has come back or stopped responding to treatment — either after at least 2 previous treatments for any B-cell lymphoma type, or after failing first-line treatment for certain aggressive types, or after a stem cell transplant using their own cells (confirm specific disease history with trial site)
• People whose doctors estimate they have more than 3 months to live
• People who are well enough to carry out basic daily activities, based on a standard medical fitness scale (ECOG score of 0–2)
• People who have at least one measurable area of lymphoma visible on a CT or MRI scan, meeting specific size requirements
• People who are willing to provide a tissue sample (either a fresh biopsy or preserved tumour tissue slides)
• People whose heart, kidneys, liver, lungs, and blood counts meet minimum function levels as tested before joining (confirm specific values with trial site)
• Women of childbearing age whose pregnancy test comes back negative, and all participants who agree to use effective contraception during treatment and for 1 year afterward
• People whose side effects from previous cancer treatments have largely resolved to mild or acceptable levels
• People with no significant inherited genetic conditions
• People who are willing and able to understand and follow the trial requirements, and who sign informed consent

Who may not be able to join:

• People who have lymphoma that has spread to the brain or spinal cord, or who have a significant history of neurological conditions such as epilepsy or stroke-related disease
• Women who are pregnant or breastfeeding, or anyone unwilling to use effective contraception during treatment and for 1 year afterward
• People who have previously had a stem cell transplant using donor cells, or an organ transplant
• People with another active cancer that is not currently in remission
• People with a primary immune deficiency or an autoimmune condition that requires immune-suppressing medication
• People who received radiation therapy within 3 months before joining
• People who received certain immunotherapy drugs (such as PD-1, PD-L1, or CD19/CD3 bispecific antibodies) within 4 weeks before joining
• People who received any immune cell-based therapy within 6 months before joining
• People whose blood tests show a positive reaction to a specific component used in the trial's cell treatment (anti-CD19 scFv)
• People who have participated in another clinical trial within 4 weeks before joining
• People with uncontrolled infections or serious illnesses, including HIV, active hepatitis B or C, heart failure, unstable chest pain, or irregular heartbeat
• People with large uncontrolled fluid build-up around the lungs or in the abdomen
• People who have had a stroke or bleeding in the brain within 3 months before joining
• People who have had major surgery or a serious injury within 28 days before joining, or who have not yet recovered from its effects
• People who received donated immune cells (such as donor lymphocyte infusion) within 6 weeks before joining
• People with a known allergy to any ingredient in the trial's cell treatment
• People with a mental or physical condition that, in the treating doctor's opinion, would prevent safe or meaningful participation in the trial
• People who are unable or unwilling to understand and sign the informed consent form
• People considered unsuitable by the trial investigators for any other reason

Important: Always verify eligibility with the trial site directly before applying.